Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11673614 | 0.79 | MAPT (0.56) | MAPTMEN1KMT2AHSD17B10KDM4E | |
| SCHEMBL9533409 | 0.70 | MAPT (0.50) | MAPTMEN1KMT2AHSD17B10KDM4E | |
| SCHEMBL20266316 | 0.70 | MAPT (0.44) | MAPTMEN1KMT2AHSD17B10KDM4E | |
| SCHEMBL9532647 | 0.68 | ADRA2A (0.37) | MAPTMEN1KMT2AHSD17B10KDM4E | |
| SCHEMBL12170102 | 0.67 | MAPT (0.50) | MAPTMEN1KMT2AHSD17B10KDM4E | |
| SCHEMBL5984487 | 0.67 | ACHE (0.39) | MAPTKMT2AHSD17B10KDM4EGAA | |
| SCHEMBL11086088 | 0.67 | MAPT (0.53) | MAPTMEN1KMT2AHSD17B10KDM4E | |
| SCHEMBL15032485 | 0.67 | MAPT (0.60) | MAPTMEN1KMT2AHSD17B10KDM4E | |
| SCHEMBL28386309 | 0.67 | MAPT (0.41) | MAPTMEN1KMT2AHSD17B10KDM4E | |
| SCHEMBL9534618 | 0.67 | POLB (0.42) | MAPTMEN1KMT2AHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5109001-A | Treating hyperactivity of excitatory neurotransmitters | NOVO NORDISK A/S (DK) | 1992-04-28 | — | — | US | claimed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| WO-2007134449-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2007-11-29 | — | — | WO | disclosed |
| EP-0348872-B1 | FUSED DIHYDROXYQUINOXALINES AND THEIR USE AS GLUTAMATE ANTAGONISTS | NOVO NORDISK A/S (DK) | 1993-09-29 | — | — | EP | disclosed |
| US-5109001-A | Treating hyperactivity of excitatory neurotransmitters | NOVO NORDISK A/S (DK) | 1992-04-28 | — | — | US | disclosed |
| US-5079250-A | TRICYCLIC HETEROCYCLIC DIOLS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-01-07 | — | — | US | disclosed |
| US-5075306-A | Nervous system, psychological disorders | NOVO NORDISK A/S (DK) | 1991-12-24 | — | — | US | disclosed |
| US-5057516-A | Nervous system disorders | NOVO NORDISK A/S (DK) | 1991-10-15 | — | — | US | disclosed |
| US-4977155-A | Nervous system disorders | A/S FERROSAN (DK) | 1990-12-11 | — | — | US | disclosed |
| EP-0348872-A1 | Fused dihydroxyquinoxalines and their use as glutamate antagonists | NOVO NORDISK A/S (DK) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | MAPT 15/4885MEN1 2310/4885KMT2A 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.